Staar Surgical Company (STAA)
What Makes Staar Surgical (STAA) a New Buy Stock
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Staar Surgical (STAA) International Revenue in Focus: Trends and Expectations
Examine Staar Surgical's (STAA) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Staar Surgical (STAA) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Staar Surgical (STAA) Reports Q2 Loss, Beats Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.33 per share a year ago.
STAAR Surgical Q1: Clouded Outlook Warrants Caution (Rating Downgrade)
Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw the earlier guidance for revenue growth of 9–15%. I expect revenue and earnings of $320 million and $23 million, respectively, for next year, which puts the current valuation at 43.5 times earnings.
STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript
STAAR Surgical Company. (NASDAQ:STAA ) Q1 2025 Earnings Conference Call May 7, 2025 5:15 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Stephen Farrell - Chair of the Board, President and CEO Warren Faust - President and COO Deborah Andrews - Interim CFO Conference Call Participants Tom Stephan - Stifel Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical First Quarter 2025 Earnings Webcast.
Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.06 per share a year ago.
STAAR Surgical Company (STAA) Q4 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q4 2024 Earnings Call Transcript February 11, 2025 5:00 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Tom Frinzi - Chair of the Board, President and CEO Patrick Williams - CFO Conference Call Participants Iseult Mcmahon - BTIG Tom Stephan - Stifel Anthony Petrone - Mizuho Macauley Kilbane - William Blair Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer Jim Sidoti - Sidoti & Co. Phillip Dantoin - Piper Sandler Jon Young - Canaccord David Saxon - Needham & Co. Mason Carrico - Stephens Operator Greetings and welcome to the STAAR Surgical Fourth Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Tuesday, February 11th, 2025.
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet.
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Shares have been under pressure lately due to weak demand from China, which is by far the company's largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster.
A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
